FDA, Lilly and weight loss
FDA rethinking block on compounding of Lilly's obesity drug
The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to investigate whether shortages of the drug, which is sold by Lilly as Mounjaro for diabetes and Zepbound for obesity, have actually been resolved as reported earlier this month.
and that those whose insurance doesn’t cover the drug can get $500 off its $1,350 list price for up to a year. As with ...
The FDA has approved PureTech Health’s ‘space occupying ... This would give it an edge on Novo’s obesity drug Saxenda (liraglutide), whose possible side effects include nausea, diarrhoea ...
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...
Rhythm Pharmaceuticals’ RYTM shares gained 8.4% on Aug. 26 after announcing the FDA ... new drug application (sNDA) for its only marketed drug, Imcivree (setmelanotide), to treat obesity ...
The U.S. Food and Drug Administration (FDA) approved the drug for weight control ... The drug has caused a lot of sensation as it attacks obesity. It was found that people on the drug ...
This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative colitis. Novo Nordisk’s NVO oral obesity pill, amycretin, showed ...
Millions of older Americans with obesity could potentially get ... and Medicaid Services and the manufacturer of FDA-approved versions of the drug. But the price that is reached in those ...
On Wednesday, the FDA announced that the drug tirzepatide, which is currently available for Type 2 diabetes patients as "Mounjaro" is now approved to treat obesity and overweight, too.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback